Skip to main content
SpringerLink
Log in

Peritransplantation Monitoring of Minimal Residual Disease in Acute Lymphoblastic Leukemia

  • Chapter
  • First Online:
Molecular Aspects of Hematologic Malignancies

Part of the book series: Principles and Practice ((PRINCIPLES))

  • 1322 Accesses

Abstract

Minimal residual disease is currently the most powerful prognostic tool enabling prediction of the outcome in acute lymphoblastic leukemia (ALL). The monitoring of minimal residual disease during and after remission induction therapy has already been implemented into modern ALL therapeutic protocols for risk group stratification, thus influencing decisions on hematopoietic stem cell transplantation, which is a treatment option reserved for high-risk and relapsed ALL patients. Moreover, there is increasing evidence of the prognostic significance of residual disease assessment performed before and after transplantation. Peritransplantation assessment enables more adequate decisions concerning conditioning for transplantation, while post-transplant monitoring creates an opportunity for early intervention in case of an increased risk of ALL relapse. Peritransplantation monitoring of minimal residual disease might also be used to assess the effectiveness of treatment aimed at relapse prevention, as well as to evaluate novel treatment modalities, including those related or alternative to hematopoietic stem cell transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C, Lamy T, Le Prise PY, Beauplet A, Bories D, Semana G, Quelvennec E (2002) Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 99(12):4618–4625

    Article  PubMed  CAS  Google Scholar 

  • Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A, Steward CG, Handgretinger R, Beck JF, Klingebiel T (2002) Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 16(9):1668–1672

    Article  PubMed  CAS  Google Scholar 

  • Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A (2009) Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 27(3):377–384. doi:10.1200/JCO.2008.17.6065 JCO.2008.17.6065 [pii]

    Article  PubMed  Google Scholar 

  • Bader P, Willasch A, Klingebiel T (2008) Monitoring of post-transplant remission of childhood malignancies: is there a standard? Bone Marrow Transplant 42(Suppl 2):S31–S34. doi:10.1038/bmt.2008.280 bmt2008280 [pii]

    Article  PubMed  Google Scholar 

  • Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A (2009) Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 113(18):4153–4162. doi:10.1182/blood-2008-11-185132 blood-2008-11-185132 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Bene MC, Kaeda JS (2009) How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. Haematologica 94(8):1135–1150. doi:10.3324/haematol.2008.004267 haematol.2008.004267 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Biondi A, Valsecchi MG, Seriu T, D’Aniello E, Willemse MJ, Fasching K, Pannunzio A, Gadner H, Schrappe M, Kamps WA, Bartram CR, van Dongen JJ, Panzer-Grumayer ER (2000) Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 14(11):1939–1943

    Article  PubMed  CAS  Google Scholar 

  • Bjorklund E, Mazur J, Soderhall S, Porwit-MacDonald A (2003) Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 17(1):138–148

    Article  PubMed  CAS  Google Scholar 

  • Campana D (2009a) Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol 46(1):100–106. doi:10.1053/j.seminhematol.2008.09.001 S0037-1963(08)00143-1 [pii]

    Article  PubMed  Google Scholar 

  • Campana D (2009b) Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23 (5):1083–1098, vii. doi:10.1016/j.hoc.2009.07.010 S0889-8588(09)00148-8 [pii]

    Google Scholar 

  • Campana D (2010a) Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010:7–12. doi:10.1182/asheducation-2010.1.7 2010/1/7 [pii]

    Article  PubMed  Google Scholar 

  • Campana D (2010b) Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep 5(3):169–176. doi:10.1007/s11899-010-0056-8

    Article  PubMed  Google Scholar 

  • Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer—Childhood Leukemia Cooperative Group. N Engl J Med 339 (9):591–598

    Google Scholar 

  • Elorza I, Palacio C, Dapena JL, Gallur L, de Toledo JS, de Heredia CD (2010) Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica 95(6):936–941. doi:10.3324/haematol.2009.010843 haematol.2009.010843 [pii]

    Article  PubMed  Google Scholar 

  • Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schafer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR (2008) Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 22(4):771–782. doi:10.1038/leu.2008.5 leu20085 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Foroni L, Hoffbrand AV (2002) Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 15(1):71–90. doi:10.1053/beha.2002.0186

    Article  PubMed  CAS  Google Scholar 

  • Foster JH, Hawkins DS, Loken MR, Wells DA (2011) Minimal residual disease detected prior to hematopoietic cell transplantation. Pediatr Blood Cancer 57(1):163–165. doi:10.1002/pbc.23079 B T

    Article  PubMed  Google Scholar 

  • Goulden N, Steward C (2002) Clinical relevance of MRD in children undergoing allogeneic stem cell transplantation for ALL. Best Pract Res Clin Haematol 15(1):59–70. doi:10.1053/beha.2002.0185 S1521692602901854 [pii]

    Article  PubMed  Google Scholar 

  • Jółkowska J, Derwich K, Dawidowska M (2007) Methods of minimal residual disease (MRD) detection in childhood haematological malignancies. J Appl Genet 48(1):77–83

    Article  PubMed  Google Scholar 

  • Jude V, Chan KW (2010) Recent advances in hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia. Curr Hematol Malig Rep 5(3):129–134. doi:10.1007/s11899-010-0050-1

    Article  PubMed  Google Scholar 

  • Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ, Jones CG, Rowbottom AW, Hunt LP, Green AF, Clarke E, Lankester AW, Cornish JM, Pamphilon DH, Steward CG, Oakhill A (1998a) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 92(11):4072–4079

    PubMed  CAS  Google Scholar 

  • Knechtli CJ, Goulden NJ, Hancock JP, Harris EL, Garland RJ, Jones CG, Grandage VL, Rowbottom AW, Green AF, Clarke E, Lankester AW, Potter MN, Cornish JM, Pamphilon DH, Steward CG, Oakhill A (1998b) Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 102(3):860–871

    Article  PubMed  CAS  Google Scholar 

  • Krejci O, van der Velden VH, Bader P, Kreyenberg H, Goulden N, Hancock J, Schilham MW, Lankester A, Revesz T, Klingebiel T, van Dongen JJ (2003) Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 32(8):849–851. doi:10.1038/sj.bmt.1704241 1704241 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJ, de Weger RA, Wijnen JT, Vossen JM, Versluys B, Egeler RM, van Tol MJ, Putter H, Revesz T, van Dongen JJ, van der Velden VH, Schilham MW (2010) Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia 24(8):1462–1469. doi:10.1038/leu.2010.133 leu2010133 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Lee S, Kim YJ, Chung NG, Lim J, Lee DG, Kim HJ, Min CK, Lee JW, Min WS, Kim CC (2009) The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 115(3):561–570. doi:10.1002/cncr.24026

    Article  PubMed  CAS  Google Scholar 

  • Lion T (2007) Detection of impending graft rejection and relapse by lineage-specific chimerism analysis. Methods Mol Med 134:197–216 1-59745-223-8:197 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, Gandini D, Prentice HG, Goldstone A, Hoffbrand AV, Foroni L (2002) Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 20(4):1094–1104

    Article  PubMed  Google Scholar 

  • Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G (2008) Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia. Leukemia 22(12):2193–2200. doi:10.1038/leu.2008.227 leu2008227 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Pulsipher MA, Bader P, Klingebiel T, Cooper LJ (2009) Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant 15(1 Suppl):62–71. doi: 10.1016/j.bbmt.2008.11.009 S1083-8791(08)00489-8 [pii]

    Article  PubMed  Google Scholar 

  • Sanchez J, Serrano J, Gomez P, Martinez F, Martin C, Madero L, Herrera C, Garcia JM, Casano J, Torres A (2002) Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 116(3):686–694 3311 [pii]

    Article  PubMed  Google Scholar 

  • Schilham MW, Balduzzi A, Bader P (2005) Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells? Bone Marrow Transplant 35(Suppl 1):S49–S52

    Article  PubMed  Google Scholar 

  • Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC, Oldani E, Grassi A, Intermesoli T, Mico C, Rossi G, Fabris P, Lambertenghi-Deliliers G, Angelucci E, Barbui T, Bassan R, Rambaldi A (2007) Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 92(5):612–618

    Article  PubMed  Google Scholar 

  • Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R, Mejstrikova E, Stary J, Trka J (2007) Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 48(1):93–100. doi:10.1002/pbc.20794

    Article  PubMed  Google Scholar 

  • Stumph J, Vnencak-Jones CL, Koyama T, Frangoul H (2008) Comparison of peripheral blood and bone marrow samples for detection of post transplant mixed chimerism. Bone Marrow Transplant 41(6):589–590

    Article  PubMed  CAS  Google Scholar 

  • Uzunel M, Jaksch M, Mattsson J, Ringden O (2003) Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. Br J Haematol 122(5):788–794 4495 [pii]

    Article  PubMed  Google Scholar 

  • Uzunel M, Mattsson J, Jaksch M, Remberger M, Ringden O (2001) The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 98(6):1982–1984

    Article  PubMed  CAS  Google Scholar 

  • van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ (2007a) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21(4):604–611

    PubMed  Google Scholar 

  • van der Velden VH, Panzer-Grumayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, Basso G, Schrappe M, Wijkhuijs JM, Konrad M, Bartram CR, Masera G, Biondi A, van Dongen JJ (2007b) Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 21(4):706–713

    PubMed  Google Scholar 

  • van der Velden VH, Joosten SA, Willemse MJ, van Wering ER, Lankester AW, van Dongen JJ, Hoogerbrugge PM (2001) Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia 15(9):1485–1487

    Article  PubMed  Google Scholar 

  • van der Velden VH, van Dongen JJ (2009) MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol 538:115–150. doi:10.1007/978-1-59745-418-6_7

    Article  PubMed  Google Scholar 

  • van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Droese J, Gonzalez D, Bastard C, White HE, Spaargaren M, Gonzalez M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17(12):2257–2317

    Article  PubMed  Google Scholar 

  • van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352(9142):1731–1738

    Article  PubMed  Google Scholar 

  • Winiarski J, Gustafsson A, Wester D, Dalianis T (2000) Follow-up of chimerism, including T- and B-lymphocytes and granulocytes in children more than one year after allogeneic bone marrow transplantation. Pediatr Transplant 4(2):132–139

    Article  PubMed  CAS  Google Scholar 

  • Yamaji K, Okamoto T, Yokota S, Watanabe A, Horikoshi Y, Asami K, Kikuta A, Hyakuna N, Saikawa Y, Ueyama J, Watanabe T, Okada M, Taga T, Kanegane H, Kogawa K, Chin M, Iwai A, Matsushita T, Shimomura Y, Hori T, Tsurusawa M (2010) Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 55(7):1287–1295. doi:10.1002/pbc.22620

    Article  PubMed  Google Scholar 

  • Zhou J, Goldwasser MA, Li A, Dahlberg SE, Neuberg D, Wang H, Dalton V, McBride KD, Sallan SE, Silverman LB, Gribben JG (2007) Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 110(5):1607–1611 10.1182/blood-2006-09-045369 blood-2006-09-045369 [pii]

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This Chapter was partly supported by the Ministry of Science and Higher Education, Grant N N407 311 839.

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Genetics, Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479, Poznań, Poland

    Małgorzata Dawidowska

  2. Department of Pediatric Oncology, Hematology and Transplantology, Poznań University of Medical Sciences, Szpitalna 27/33, 60-572, Poznań, Poland

    Katarzyna Derwich

  3. Department of Pediatric Hematology and Oncology, Medical University of Silesia, 3 Maja 13/15, 41-800, Zabrze, Poland

    Tomasz Szczepański

Authors
  1. Małgorzata Dawidowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katarzyna Derwich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomasz Szczepański
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Małgorzata Dawidowska .

Editor information

Editors and Affiliations

  1. International Institute of Molecular and, Trojdena 4, Warszawa, 02-109, Poland

    Michal Witt

  2. , Institute of Human Genetics, Polish Academy of Sciences, ul. Strzeszynska 32, Poznan, 60479, Poland

    Malgorzata Dawidowska

  3. , Department of Pediatric Hematology, Silesian Academy of Medicine, 3 Maja 13-15, Zabrze, 41800, Poland

    Tomasz Szczepanski

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dawidowska, M., Derwich, K., Szczepański, T. (2012). Peritransplantation Monitoring of Minimal Residual Disease in Acute Lymphoblastic Leukemia. In: Witt, M., Dawidowska, M., Szczepanski, T. (eds) Molecular Aspects of Hematologic Malignancies. Principles and Practice. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29467-9_16

Download citation

Publish with us

Policies and ethics

Search

Navigation